Last reviewed · How we verify
Oral Topotecan
Oral topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cancer cell death.
Oral topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cancer cell death. Used for Small cell lung cancer, Ovarian cancer, Cervical cancer.
At a glance
| Generic name | Oral Topotecan |
|---|---|
| Also known as | Hycamtin, Hycamtin Capsules, Oral Hycamtin, Hycamtin capsules |
| Sponsor | Accelerated Community Oncology Research Network |
| Drug class | Topoisomerase I inhibitor |
| Target | Topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Topotecan is a camptothecin derivative that binds to and stabilizes the topoisomerase I-DNA complex, preventing DNA religation and leading to double-strand breaks during replication. This results in apoptosis of rapidly dividing cancer cells. The oral formulation provides an alternative to intravenous administration, potentially improving patient convenience and tolerability.
Approved indications
- Small cell lung cancer
- Ovarian cancer
- Cervical cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Abdominal pain
Key clinical trials
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (PHASE2)
- Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer (PHASE1)
- Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs (PHASE2)
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma (PHASE1)
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes (PHASE1)
- Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |